[go: up one dir, main page]

WO2003052064A3 - Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media - Google Patents

Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media Download PDF

Info

Publication number
WO2003052064A3
WO2003052064A3 PCT/US2002/039496 US0239496W WO03052064A3 WO 2003052064 A3 WO2003052064 A3 WO 2003052064A3 US 0239496 W US0239496 W US 0239496W WO 03052064 A3 WO03052064 A3 WO 03052064A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell lines
chemically defined
defined media
myeloma cell
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/039496
Other languages
French (fr)
Other versions
WO2003052064A2 (en
Inventor
Chichang Lee
Celia Ly
Gordon Moore
Edward Savino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to AU2002362130A priority Critical patent/AU2002362130A1/en
Priority to EP02797264A priority patent/EP1490481A4/en
Priority to JP2003552931A priority patent/JP2005512538A/en
Priority to CA002470026A priority patent/CA2470026A1/en
Publication of WO2003052064A2 publication Critical patent/WO2003052064A2/en
Anticipated expiration legal-status Critical
Publication of WO2003052064A3 publication Critical patent/WO2003052064A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to clonal myeloma cell lines that have the ability to grow continuously in chemically defined media. The present invention also relates to the production of proteins in clonal myeloma cell lines and any cell lines derived therefrom. The present invention further relates to methods for identifying cell lines capable of growing in chemically defined media. The present invention also relates to business methods where customers are provided with the cells, cell lines, and cell cultures of the present invention.
PCT/US2002/039496 2001-12-14 2002-12-11 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media Ceased WO2003052064A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002362130A AU2002362130A1 (en) 2001-12-14 2002-12-11 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
EP02797264A EP1490481A4 (en) 2001-12-14 2002-12-11 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
JP2003552931A JP2005512538A (en) 2001-12-14 2002-12-11 A clonal myeloma cell line useful for producing proteins in serum-free medium
CA002470026A CA2470026A1 (en) 2001-12-14 2002-12-11 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33942901P 2001-12-14 2001-12-14
US60/339,429 2001-12-14

Publications (2)

Publication Number Publication Date
WO2003052064A2 WO2003052064A2 (en) 2003-06-26
WO2003052064A3 true WO2003052064A3 (en) 2004-10-28

Family

ID=23328968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039496 Ceased WO2003052064A2 (en) 2001-12-14 2002-12-11 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media

Country Status (5)

Country Link
EP (1) EP1490481A4 (en)
JP (1) JP2005512538A (en)
AU (1) AU2002362130A1 (en)
CA (1) CA2470026A1 (en)
WO (1) WO2003052064A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678570B2 (en) 2004-03-01 2010-03-16 Kitakyushu Foundation For The Advancement Of Industry, Science And Technology Human cell strains for protein production, provided by selecting strains with high intracellular protein and mutating with carcinogens
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
CA2576464C (en) * 2004-07-23 2014-09-09 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
EP2970409A2 (en) 2013-03-15 2016-01-20 Bioven 3 Limited Self-assembling synthetic proteins

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4504469A (en) * 1982-12-21 1985-03-12 Ferring Ab Vasotocin derivatives
US4780313A (en) * 1985-12-24 1988-10-25 Takeda Chemical Industries, Ltd. Method of stimulating the immune system with a mixture of substances having IL-2 activity and muramyldipeptide
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5723441A (en) * 1993-11-15 1998-03-03 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US5759996A (en) * 1994-04-13 1998-06-02 La Jolla Cancer Research Center Peptides useful for altering αv β3 -mediated binding
US5877148A (en) * 1994-08-05 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US6008195A (en) * 1996-02-16 1999-12-28 The Regents Of University Of California Antimicrobial peptides and methods of use
US6274335B1 (en) * 1982-05-05 2001-08-14 Genentech, Inc. Method of treatment using recombinant human tissue plasminogen activator
US6306648B1 (en) * 1996-06-03 2001-10-23 St. Jude Children's Research Hospital Cyclin-C variants, and diagnostic and therapeutic uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900056B2 (en) * 2001-02-15 2005-05-31 Centocor, Inc. Chemically defined medium for cultured mammalian cells

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274335B1 (en) * 1982-05-05 2001-08-14 Genentech, Inc. Method of treatment using recombinant human tissue plasminogen activator
US4504469A (en) * 1982-12-21 1985-03-12 Ferring Ab Vasotocin derivatives
US4780313A (en) * 1985-12-24 1988-10-25 Takeda Chemical Industries, Ltd. Method of stimulating the immune system with a mixture of substances having IL-2 activity and muramyldipeptide
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5723441A (en) * 1993-11-15 1998-03-03 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US5759996A (en) * 1994-04-13 1998-06-02 La Jolla Cancer Research Center Peptides useful for altering αv β3 -mediated binding
US5877148A (en) * 1994-08-05 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US6008195A (en) * 1996-02-16 1999-12-28 The Regents Of University Of California Antimicrobial peptides and methods of use
US6306648B1 (en) * 1996-06-03 2001-10-23 St. Jude Children's Research Hospital Cyclin-C variants, and diagnostic and therapeutic uses thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY PROGRESS, vol. 16, no. 5, September 2000 (2000-09-01) - October 2000 (2000-10-01), pages 682 - 687 *
BLOOD, vol. 96, no. 11, PART 2, 16 November 2000 (2000-11-16), pages 278B *
CLINICAL THERAPEUTICS, vol. 21, no. 6, June 1999 (1999-06-01), pages 932 - 942 *
CYTOTECHNOLOGY, vol. 22, no. 1-3, January 1996 (1996-01-01), pages 239 - 250 *
DATABASE BIOSIS [online] BIOLOGICAL ABSTRACTS INC. (COLUMBUS, OH USA); HILL M.: "Adaptive state of mammalian cells and its nonseparability suggestive of a quantum system", XP002972612, accession no. STN Database accession no. 2001:152166 *
DATABASE BIOSIS [online] BIOLOGICAL ABSTRACTS INC. (COLUMBUS, OH USA); LOUIS ET AL.: "Maintenance of clonotypic myeloma cells in serum-free media", XP002972615, accession no. STN Database accession no. 2001:311437 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); FAULDS ET AL.: "Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease", XP002972617, accession no. STN Database accession no. 95094637 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); MOUSER ET AL.: "Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease", XP002972616, accession no. STN Database accession no. 1999367230 *
DATABASE SCISEARCH [online] THOMSON ISI (COLUMBUS, OH, USA); GORFIEN ET AL.: "Growth of NSO cells in protein-free, chemically defined medium", XP002972614, accession no. STN Database accession no. 2000:780843 *
DATABASE SCISEARCH [online] THOMSON ISI (COLUMBUS, OH, USA); ZHOU ET AL.: "Large scale production of recombinant mouse and rat growth hormone by fed-batch GS-NS0 cell cultures", XP002972618, accession no. STN Database accession no. 97:138896 *
DRUGS, vol. 48, no. 4, October 1994 (1994-10-01), pages 583 - 598 *
FRESHNEY R. IAN, 1994, WILEY-LISS, NEW YORK, article "Culture of animal cells", pages: 92 - 93, XP002972613 *
SCRIPTA MEDICA (BRNO), vol. 73, no. 4, 2000, pages 211 - 222 *
See also references of EP1490481A4 *

Also Published As

Publication number Publication date
AU2002362130A1 (en) 2003-06-30
WO2003052064A2 (en) 2003-06-26
CA2470026A1 (en) 2003-06-26
EP1490481A2 (en) 2004-12-29
EP1490481A4 (en) 2005-12-07
JP2005512538A (en) 2005-05-12

Similar Documents

Publication Publication Date Title
EP1360314A4 (en) Chemically defined medium for cultured mammalian cells
WO2005116073A3 (en) Pdx1 expressing endoderm
WO2007079183A3 (en) Placental stem cell populations
DE69937966D1 (en) PRODUCTION OF LYMPHOIDER TISSUE-SPECIFIC CELLS OF HEMATOPOIETIC PRECURSOR CELLS IN A THREE-DIMENSIONAL SYSTEM
AU2002336930A1 (en) Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture
SG151259A1 (en) Cardiomyocyte production
WO2005003320A3 (en) Neuronal differentiation of stem cells
WO2006029198A3 (en) Culturing human embryonic stem cells
WO2007070315A3 (en) Improved production of glycoproteins using manganese
GB2432846A (en) Medium and culture of embryonic stem cells
EP2722387A3 (en) Definitive endoderm
WO2007050498A3 (en) Methods of protein production using anti-senescence compounds
AU2019268061A1 (en) Placental stem cell populations
WO2001021760A3 (en) Cell culture spinner flasks
WO2003064630A3 (en) Cell culture medium
WO2003052064A3 (en) Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
WO2007016366A3 (en) Defined culture conditions of human embryonic stem cells
WO2004011637A3 (en) Modified adamts4 molecules and method of use thereof
WO2004053080A3 (en) Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
WO2003051720A3 (en) A myeloma cell line useful for manufacturing recombinant proteins in chemically defined media
AU4816201A (en) Production of tcr gamma delta t cells
WO2004003217A8 (en) Glutathione production
WO2003100010A3 (en) Cytokine-free growth and maintenance of progenitor cells
EP2377922A3 (en) PDX1 expressing endoderm
WO2007095336A3 (en) Production of hiv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002362130

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2470026

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003552931

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002797264

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797264

Country of ref document: EP